• Cefpodoxime sodium salt packaged and labeled.

click on thumbnail to zoom
SKU: C096

  Click 'Bulk Order' for 10 or more
Price: make selection(s)

Cefpodoxime Sodium is a broad-spectrum, third-generation cephalosporin β-lactam antibiotic that interferes with bacterial cell wall.  It is effective against a wide range of Gram-positive and Gram-negative bacteria.  Cefpodoxime Sodium is soluble in DMSO.

We also offer:

  •  Cefpodoxime Proxetil (C015)
  •  Cefpodoxime Free Acid (C016)

    CAS Number


    Molecular Formula


    Molecular Weight


    Mechanism of Action

    Like β-lactams, cephalosporins interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBP’s are enzymes which catalyze a pentaglycine crosslink between alanine and lysine residues providing additional strength to the cell wall. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Resistance to cephalosporins is commonly due to cells containing plasmid encoded β-lactamases. However, like many cephalosporins, cefpodoxime is stable in the presence of β-lactamases.

    Storage Conditions

    -20°C. Protect from light.

    Tariff Code



    Cefpodoxime Sodium is a broad-spectrum antibiotic which targets a wide variety of Gram-positive and Gram-negative bacteria especially those which cause otitis media and pharyngitis.


    Microbiology Applications

    Cefpodoxime Sodium is commonly used in clinical in vitromicrobiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options. Representative MIC values include:

    • Klebsiella pneumoniae 8 µg/mL - 64 µg/mL
    • Haemophilus influenzae 0.032 µg/mL – 1 µg/mL
    • For a complete list of cefpodoxime MIC values, click here.

    Cefpodoxime from TOKU-E was used as a reference compound when characterizing the extended-spectrum AmpC (ESAC) B-lactamase enzymes (Lahiri et al, 2014).

    In vitro kinetic modeling can be used to study the pharmacokinetic-pharmacodynamic modelling of the antibacterial activity of cefpodoxime.  This approach has more detailed information than the MIC about he time course of efficacy (Liu et al, 2005).





    brown crystalline powder



    Impurity Profile

    report single impurity

    Water Content (Karl Fischer)

    report results


    (HPLC) Report results



    Georgopapadakou NH (1992)  Mechanisms of action of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines in Escherichia coli. Antimicrob. Agents. Chemother. 37(3):559-565

    Lahiri SD, Giacobbe RA, Johnstone MR and Alm RA (2014)  Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C β-lactamase enzyme. J. Antimicrob. Chemother. 69(11):2942–2946  PMID

    Liu P, Rand KH, Obermann B and Derendorf H (2005)  Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int. J. Antimicrob. Agents 25(2):120-129  PMID 15664481

    Wise R,  Andrews JM, Ashby JP and Thornber D (1990)  The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins.  J. Antimicrob. Chemother.  25(4):541–550  PMID 2351624

    Alm et al. used cefpodoxime from TOKU-E against Escherichia coli NDM isolates in microdilution MIC assays. "Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3."

Other Items In This Category